ロード中...
Efficacy and safety of pegylated interferon α and ribavirin in patients monoinfected with HCV genotype 4
INTRODUCTION: Dual therapy (PegIFN and ribavirin) (DT) was the standard of care in patients infected with HCV genotype 4 (HCV-4) until 2014. Nowadays, new treatment options are available including interferon (IFN)-based and other IFN-free regimens. AIM: To assess the efficacy (SVR24) and safety of D...
保存先:
| 出版年: | Prz Gastroenterol |
|---|---|
| 主要な著者: | , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Termedia Publishing House
2018
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5894449/ https://ncbi.nlm.nih.gov/pubmed/29657607 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5114/pg.2018.74558 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|